Mobile

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

Update Il y a 4 ans
Reference: NCT01928537

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

This study will examine the effect intravenously administered rigosertib has on the relationship between bone marrow blasts response and overall survival in myelodysplastic syndromes (MDS) patients who have 5-30% bone marrow blasts and who progressed on or after treatment with azacitidine or decitabine.

Inclusion criteria

  • Myelodysplastic syndromes,Refractory Anemia With Excess Blasts,Chronic myelomonocytic leukemia,Cytopenia

Links